The Uromigos

401 Episoder

1. Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide

   Publisert: 5.6.2023
2. Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer

   Publisert: 5.6.2023
3. Episode 241: Statistics for clinical trials

   Publisert: 1.6.2023
4. Episode 240: Preview of GU Cancer at ASCO 2023

   Publisert: 30.5.2023
5. Episode 239: The STAMPEDE trial

   Publisert: 22.5.2023
6. Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy

   Publisert: 14.5.2023
7. Episode 237: 2023 AUA Highlights

   Publisert: 9.5.2023
8. Episode 236: ODAC for olaparib

   Publisert: 2.5.2023
9. Episode 235: Danny Heng and the IMDC classification in renal cancer

   Publisert: 24.4.2023
10. Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer

    Publisert: 19.4.2023
11. Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico

    Publisert: 15.4.2023
12. Episode 232: Belzutifan in early and late renal cancer

    Publisert: 14.4.2023
13. Episode 231: Ursula Vogl, MD in the Rising Star Series

    Publisert: 5.4.2023
14. Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand

    Publisert: 28.3.2023
15. Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer

    Publisert: 20.3.2023
16. Episode 228: Karine Tawagi, MD in the Rising Star Series

    Publisert: 15.3.2023
17. Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden

    Publisert: 6.3.2023
18. Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George

    Publisert: 27.2.2023
19. Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC

    Publisert: 20.2.2023
20. Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger

    Publisert: 20.2.2023